A Meta-Analysis of the Effectiveness and Safety of Sintilimab Combined with Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer

The meta-analysis evaluated the safety and effectiveness of Sintilimab combined with chemotherapy for advanced non-small cell lung cancer (NSCLC). The study found that while patients receiving Sintilimab had a 5.14 times higher risk of hypothyroidism, other adverse effects like hematologic toxicity and hepatic impairment were not significantly different from chemotherapy alone. Gastrointestinal and alopecia adverse reactions were potentially less frequent. However, there was an increased risk of pneumonia, proteinuria, rash, and infusion reactions. Importantly, Sintilimab combined with chemotherapy improved objective response rate (ORR), disease control rate (DCR), and prolonged median overall survival (mOS) and median progression-free survival (mPFS) in NSCLC patients, indicating that the combination is efficacious, safe, and manageable.